Maillard reactions in pharmaceutical formulations and human health
1Bernard J. Dunn School of Pharmacy Shenandoah University Winchester, Virginia.
Abstract:
This article reviews pharmaceutical and health implications of the nonenzymatic Maillard reaction, also referred to as browning or N-glycation. The spontaneous Maillard reaction between reducing sugars and amines was first reported by French scientist Louis Maillard in 1912; the Maillard reaction may also occur with other drugs. Hemoglobin A1c and chemically complex colored products that follow initial dextrose and amino acids adducts in parenteral nutrition solutions are the advanced maillard products most familiar to pharmacists.
More Related Videos
Related Concept Videos
Phase I Reactions: Oxidation of Carbon-Heteroatom and Miscellaneous Systems
In carbon-nitrogen systems, aliphatic and aromatic amines can undergo oxidative reactions. Secondary and tertiary amines, like those found in tricyclic antidepressants, can undergo N-dealkylation, a process that involves the oxidation of the alkyl group. In addition, oxidative...
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview
Modified-Release Drug Delivery Systems: Bioavailability
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...


